Tudor Investment Corp ET AL Makes New $399,000 Investment in Relay Therapeutics, Inc. $RLAY

Tudor Investment Corp ET AL acquired a new position in Relay Therapeutics, Inc. (NASDAQ:RLAY) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 76,446 shares of the company’s stock, valued at approximately $399,000.

A number of other large investors have also added to or reduced their stakes in RLAY. AQR Capital Management LLC increased its stake in Relay Therapeutics by 11.9% in the 1st quarter. AQR Capital Management LLC now owns 364,946 shares of the company’s stock worth $956,000 after acquiring an additional 38,812 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Relay Therapeutics by 6.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 84,069 shares of the company’s stock worth $221,000 after acquiring an additional 5,238 shares during the last quarter. Millennium Management LLC increased its stake in Relay Therapeutics by 14.6% in the 1st quarter. Millennium Management LLC now owns 2,942,875 shares of the company’s stock worth $7,710,000 after acquiring an additional 374,491 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in Relay Therapeutics in the 1st quarter worth approximately $53,000. Finally, Woodline Partners LP increased its stake in Relay Therapeutics by 448.4% in the 1st quarter. Woodline Partners LP now owns 1,518,561 shares of the company’s stock worth $3,979,000 after acquiring an additional 1,241,657 shares during the last quarter. Institutional investors own 96.98% of the company’s stock.

Insider Transactions at Relay Therapeutics

In other news, insider Peter Rahmer sold 11,684 shares of Relay Therapeutics stock in a transaction that occurred on Tuesday, January 27th. The stock was sold at an average price of $7.62, for a total value of $89,032.08. Following the completion of the transaction, the insider owned 277,964 shares in the company, valued at approximately $2,118,085.68. The trade was a 4.03% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Thomas Catinazzo sold 17,717 shares of Relay Therapeutics stock in a transaction that occurred on Tuesday, April 7th. The stock was sold at an average price of $13.01, for a total value of $230,498.17. Following the completion of the transaction, the chief financial officer owned 213,867 shares of the company’s stock, valued at approximately $2,782,409.67. This trade represents a 7.65% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 69,651 shares of company stock worth $644,279. 4.87% of the stock is currently owned by company insiders.

Relay Therapeutics Stock Performance

Shares of Relay Therapeutics stock opened at $16.11 on Friday. The stock has a market cap of $2.88 billion, a price-to-earnings ratio of -9.94 and a beta of 1.57. The stock has a 50 day moving average price of $10.66 and a 200-day moving average price of $8.49. Relay Therapeutics, Inc. has a one year low of $2.53 and a one year high of $16.49.

Relay Therapeutics (NASDAQ:RLAY) last announced its earnings results on Thursday, February 26th. The company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.06. The company had revenue of $7.00 million during the quarter, compared to analysts’ expectations of $4.34 million. Sell-side analysts predict that Relay Therapeutics, Inc. will post -2.55 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on RLAY shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Relay Therapeutics in a research note on Wednesday, April 8th. Wells Fargo & Company lifted their price objective on Relay Therapeutics from $15.00 to $17.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 17th. JonesTrading started coverage on Relay Therapeutics in a research note on Tuesday. They issued a “hold” rating and a $18.00 price objective on the stock. Guggenheim lifted their price objective on Relay Therapeutics from $15.00 to $22.00 and gave the stock a “buy” rating in a research note on Friday, March 13th. Finally, Citizens Jmp lifted their price objective on Relay Therapeutics from $15.00 to $17.00 and gave the stock a “market outperform” rating in a research note on Tuesday, March 17th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Relay Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $18.38.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.